Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Checking in on Belbuca's launch: A follow-up visit with our expert from April 4th 2016

Ticker(s): BDSI, ENDP, COLL

Who's the expert?

Institution: Duke University

  • Associate Professor of Anesthesiology and Director of Interventional Pain.
  • Extensive research experience performing both investigator-initiated and industry sponsored studies, has led two clinical trials that examined the efficacy of pain medicine in surgical and non-surgical patient.
  • Expert on current standards for opioid management; has authored numerous articles in peer reviewed journals.

Interview Questions
Q1.

How many patients do you currently manage pain for?

Added By: joe_mccann
Q2.

What's your high level view of Belbuca now that you have had a few months to prescribe it?

Added By: joe_mccann
Q3.

How many patients have you prescribed Belbuca?  How does this align with your expectations in April?

Added By: joe_mccann
Q4.

What are  present and emerging alternatives to Belbuca, and how might  Belbuca stack up?

Added By: rocks3

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.